Evaluation of Efficacy, Safety, and Tolerability of Fixed Dose Combination (FDC) of Halometasone 0.05% and Fusidic Acid 2% W/W Topical Cream Versus FDC of Betamethasone Valerate 0.12% and Neomycin Sulphate 0.5% W/W Topical Cream in the Treatment of Infected Eczematous Dermatosis in Indian Subjects: A Randomized Open-Label Comparative Phase III Multi-Centric Trial

Documenti analoghi

• Halometasone 0.05% Cream in Eczematous Dermatoses
  di: THE EXECARE WORKING GROUP,
  Pubblicazione: (2013)
• EFFICACY AND SAFETY OF TOPICAL HALOMETASONE IN ECZEMATOUS DERMATOSES IN INDIAN POPULATION: AN OPEN LABEL, NONCOMPARATIVE STUDY
  di: Jerajani, H R, et al.
  Pubblicazione: (2011)
• Halometasone monohydrate (0.05%) in occupational contact dermatitis
  di: Maiti, Rituparna, et al.
  Pubblicazione: (2016)
• Efficacy and Safety of Halometasone Cream to Treat Chronic Generalized Eczema and the Effects of Halometasone Cream on Serum Cortisol Levels
  di: Li, Yan, et al.
  Pubblicazione: (2017)
• A Comparison of Betamethasone Valerate 0.1% Cream Twice Daily Plus Oral Simvastatin Versus Betamethasone Valerate 0.1% Cream Alone in the Treatment of Vitiligo Patients
  di: Iraji, Fariba, et al.
  Pubblicazione: (2017)